PARP1 and neoplasm: Therefore, the premise of combining olaparib and bevacizumab is based on the rationale that direct targeting of PARP by olaparib and indirect sensitisation to olaparib by acquisition of HR defects by bevacizumab will be therapeutically beneficial, and pragmatism as bevacizumab is incorporated into standard-of-care treatments in tumour types that PARP inhibitors have potential to be effective.